The pragmatic use of apomorphine at the end of life

Palliative Medicine

Volumn 23, Issue 8, 2009, Pages 777-779

  Dewhurst, F ^a   Lee, M ^b   Wood, B ^a  

^a NORTHUMBRIA HEALTHCARE NHS FOUNDATION TRUST   (United Kingdom)

^b St Benedict's Hospice   (United Kingdom)

Author keywords

Apomorphine; End of life care; Palliation; Parkinson?s disease

Indexed keywords

APOMORPHINE; DOMPERIDONE; LEVODOPA; PERGOLIDE; ROTIGOTINE; SELEGILINE;

AGED; AGITATION; ARTICLE; CASE REPORT; DEATH; DETERIORATION; DISEASE DURATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; DYSKINESIA; DYSPHAGIA; HUMAN; MALE; NAUSEA; PARKINSON DISEASE; PARKINSONISM; TACHYCARDIA; TACHYPNEA; TERMINAL CARE; URINARY TRACT INFECTION;

AGED; ANTIEMETICS; ANTIPARKINSON AGENTS; APOMORPHINE; BLINKING; DEGLUTITION DISORDERS; DOMPERIDONE; HUMANS; HYPOKINESIA; MALE; NAUSEA; PARKINSON DISEASE; TERMINAL CARE;

EID: 74849120836     PISSN: 02692163     EISSN: None     Source Type: Journal    
DOI: 10.1177/0269216309106979     Document Type: Article

References (19)

1. Tanner CM Epidemiology of Parkinson?s disease. Neurol Clin 1992 ; 10: 317-329.
2. MacMahon DG, Thomas S. Practical approaches to quality of life in Parkinson?s Disease: the nurses role. J Neurol 1998 ; 245 (suppl 1). S19 - S22.
3. National Institute of Clinical Excellence. Parkinson?s Disease: Diagnosis and Management in Primary and Secondary Care, 2005. http://www.nice.org.uk/ page.aspx?o=267744
4. Lee MA, Walker RW, Hildreth AJ, Prentice WM A survey of pain in idiopathic Parkinson?s disease (IPD). J Pain Symptom Manage 2006 ; 32: 462-469.
5. Lee MA, Walker RW, Hildreth AJ, Prentice WM Individualised assessment of quality of life in idiopathic Parkinson?s disease (IPD). Movement Disorders 2006 ; 21: 1929-1934.
6. Lee MA, Prentice WM, Hildreth AJ, Walker RW Measuring symptom load in idiopathic Parkinson?s disease. Parkinsonism Relat Disorders 2007 ; 13: 284-289.
7. Ellershaw JE, Ward C. Care of the dying: the last hours or days of life. BMJ 2003 ; 326: 30-34.
8. Munchau A., Bhatia KP Pharmacological treatment of Parkinson?s disease. Postgrad Med J 2000 ; 76: 602-610.
9. Obering CD, Chen JJ, Swope DM Update of apomorphine for the rapid treatment of hypomobility (off?) episodes in Parkinson?s disease. Pharmacotherapy 2006 ; 26: 840-852.
10. Chen JJ, Obering C. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson?s disease. Clin Therapy 2005 ; 27: 1710-1724.
11. Deleu D., Hanssens Y., Northway MG Subcutaneous apomorphine: an evidence based review of its use in Parkinson?s disease. Drugs Aging 2004 ; 21: 687-709.
12. McGee P. Apomorphine treatment: a nurse?s perspective. ACNR 2002 ; 2: 02.
13. Tyne HL, Parsons J., Sinnott A., Fox S., Fletcher N., Steiger MJ A 10 year retrospective audit of long term apomorphine use in Parkinson?s disease. J Neurol 2004 ; 251: 1370-1374.
14. Broussolle E., Marion MH, Pollak P. Continuous subcutaneous apomorphine as replacement for levodopa in severe parkinsonian patients after surgery. Lancet 1992 ; 340: 859-860.
15. Poewe W., Wenning GK Apomorphine: an underutilised therapy for Parkinson?s disease. Mov Disord 2000 ; 15: 789-794.
16. Reuter I., Ellis C., Chaudhuri K. Nocturnal subcutaneous apomorphine infusion in Parkinson?s disease and restless legs syndrome. Acta Neurologica Scandinavica 1999 ; 100: 163-167.
17. Gonsalkorale M. Palliative care in Parkinson?s disease. CME Geriatric Med 2005 ; 7: 22-28.
18. Galvez-Jimenez N., Lang AE Perioperative problems in Parkinson?s disease and their management. Apomorphine with rectal domperidone. Can J Neurolog Sci 1996 ; 23: 198-203.
19. Nicholson G., Pereira AC, Hall GM Parkinson?s disease and anaesthesia. Br J Anaesth 2002 ; 89: 904-916.